Axicabtagene Ciloleucel
Primary Mediastinal Large B-Cell Lymphoma
AIDS Malignancy ConsortiumCell therapyPhase 2Active
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
80 Active assets in the Primary Mediastinal Large B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ISOCYCLOPHOSPHAMIDE David Bond, MD | Phase 4 | BBB |
Etoposide University of Washington | Phase 4 | BBB |
Adriamycin University of Washington | Phase 4 | BBB |
(+)-VINCRISTINE Sun Yat-sen University | Phase 4 | BBB |
Vincristine sulfate National Research Center for Hematology, Russia | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Axicabtagene Ciloleucel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →